These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25698905)

  • 21. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism.
    Bistervels IM; Bavalia R; Gebel M; Lensing AWA; Middeldorp S; Prins MH; Coppens M
    J Thromb Haemost; 2022 Jun; 20(6):1376-1384. PubMed ID: 35253983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
    Bamber L; Muston D; McLeod E; Guillermin A; Lowin J; Patel R
    Thromb J; 2015; 13():20. PubMed ID: 26074735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statin treatment and the risk of recurrent pulmonary embolism.
    Biere-Rafi S; Hutten BA; Squizzato A; Ageno W; Souverein PC; de Boer A; Gerdes VE; Büller HR; Kamphuisen PW
    Eur Heart J; 2013 Jun; 34(24):1800-6. PubMed ID: 23396492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Haupt V; Schneider J; Turpie AG
    Thromb J; 2014; 12():16. PubMed ID: 25093014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of recurrent venous thromboembolism and major bleeding according to risk factor profiles in Asian patients: a subgroup analysis EINSTEIN-Extension and EINSTEIN-CHOICE.
    Yamada N; Fu W; Shi Z; Park KH; Kim HS; Dai X; Lensing AW; Pap AF; Kohno T; Tajima T; Watakabe T; Mitsumori T
    Thromb J; 2024 Jun; 22(1):48. PubMed ID: 38844941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban and the EINSTEIN clinical trial programme.
    Cohen AT; Bauersachs R
    Blood Coagul Fibrinolysis; 2019 Apr; 30(3):85-95. PubMed ID: 30920394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism.
    Solms A; Willmann S; Reinecke I; Spiro TE; Peters G; Weitz JI; Mueck W; Garmann D; Schmidt S; Zhang L; Fox KAA; Berkowitz SD
    J Thromb Thrombolysis; 2020 Jul; 50(1):1-11. PubMed ID: 32323191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE).
    Thom K; Lensing AWA; Nurmeev I; Bajolle F; Bonnet D; Kenet G; Massicotte MP; Karakas Z; Palumbo JS; Saracco P; Amedro P; Chain J; Chan AK; Ikeyama T; Lam JCM; Gauger C; Pap ÁF; Majumder M; Kubitza D; Smith WT; Berkowitz SD; Prins MH; Monagle P; Young G; Male C
    Blood Adv; 2020 Oct; 4(19):4632-4639. PubMed ID: 33002131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin treatment and risk of recurrent venous thromboembolism: a nationwide cohort study.
    Nguyen CD; Andersson C; Jensen TB; Gjesing A; Schjerning Olsen AM; Malta Hansen C; Büller H; Torp-Pedersen C; Gislason GH
    BMJ Open; 2013 Nov; 3(11):e003135. PubMed ID: 24202053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims cohort study.
    Coleman CI; Peacock WF; Bunz TJ; Beyer-Westendorf J
    Thromb Res; 2018 Aug; 168():31-36. PubMed ID: 29883907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spotlight on advances in VTE management: CALLISTO and EINSTEIN CHOICE.
    Bach M; Bauersachs R
    Thromb Haemost; 2016 Sep; 116(Suppl. 2):S24-S32. PubMed ID: 27623682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P; Lensing AWA; Thelen K; Martinelli I; Male C; Santamaría A; Samochatova E; Kumar R; Holzhauer S; Saracco P; Simioni P; Robertson J; Grangl G; Halton J; Connor P; Young G; Molinari AC; Nowak-Göttl U; Kenet G; Kapsa S; Willmann S; Pap AF; Becka M; Twomey T; Beyer-Westendorf J; Prins MH; Kubitza D;
    Lancet Haematol; 2019 Oct; 6(10):e500-e509. PubMed ID: 31420317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
    ; Büller HR; Prins MH; Lensin AW; Decousus H; Jacobson BF; Minar E; Chlumsky J; Verhamme P; Wells P; Agnelli G; Cohen A; Berkowitz SD; Bounameaux H; Davidson BL; Misselwitz F; Gallus AS; Raskob GE; Schellong S; Segers A
    N Engl J Med; 2012 Apr; 366(14):1287-97. PubMed ID: 22449293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.
    Migita S; Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
    Thromb J; 2023 Aug; 21(1):88. PubMed ID: 37599351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients.
    Ten Cate H; Lensing AWA; Weitz JI; Middeldorp S; Beyer-Westendorf J; Kubitza D; Brighton T; Raskob GE; Mismetti P; Prandoni P; Gebel M; Prins MH
    Thromb Res; 2018 Oct; 170():75-83. PubMed ID: 30121419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.
    Khorana AA; Berger JS; Wells PS; Seheult R; Ashton V; Laliberté F; Crivera C; Lejeune D; Schein J; Wildgoose P; Lefebvre P; Kaatz S
    Clin Ther; 2017 Jul; 39(7):1396-1408. PubMed ID: 28645879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
    Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
    Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.